Corporate Profile

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Recent News

  • May 27, 2020

    Novavax acquires Praha Vaccines in Czech Republic Annual operating capacity of over 1 billion doses of COVID-19 vaccine antigen GAITHERSBURG, Md. , May 27, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious...More>>

  • May 25, 2020

    First participants enrolled in Phase 1 portion of clinical trial of NVX‑CoV2373 Preliminary immunogenicity and safety results expected in July 2020 Phase 2 portion to begin promptly following successful Phase 1 results GAITHERSBURG, Md. , May 25, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

  • May 11, 2020

    CEPI increases investment up to $388 million for NVX‑CoV2373 vaccine development & manufacturing NVX ‑ CoV2373 Phase I trial initiating in May with preliminary results in July NanoFlu recently achieved all primary endpoints in pivotal Phase 3 clinical trial Company to host conference call today at...More>>

Stock Quote